Cytek Biosciences Inc (CTKB)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -6,019 | -10,159 | -17,556 | -11,510 | -12,148 | -14,122 | -6,000 | -2,210 | 2,439 | -865 | -936 | 2,332 | 4,592 | 9,966 | 14,911 | 20,352 | 19,411 |
| Total stockholders’ equity | US$ in thousands | 395,737 | 385,463 | 389,123 | 392,614 | 393,064 | 415,524 | 424,179 | 423,460 | 425,295 | 416,447 | 411,027 | 407,236 | 406,458 | 403,055 | -11,300 | -15,072 | -16,028 |
| ROE | -1.52% | -2.64% | -4.51% | -2.93% | -3.09% | -3.40% | -1.41% | -0.52% | 0.57% | -0.21% | -0.23% | 0.57% | 1.13% | 2.47% | — | — | — |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-6,019K ÷ $395,737K
= -1.52%
The return on equity (ROE) of Cytek Biosciences Inc has experienced a downward trend over the past few years. From a positive level of 2.47% in September 30, 2021, the ROE steadily declined to negative territory, reaching -1.52% by December 31, 2024.
This decline in ROE indicates that the company's ability to generate profit from its shareholders' equity has weakened. A negative ROE suggests that the company is not efficiently utilizing its equity capital to generate profits for the shareholders.
It is important for stakeholders to closely monitor the factors impacting Cytek Biosciences Inc's ROE and assess the company's financial performance and strategies to improve profitability and shareholder returns in the future.
Peer comparison
Dec 31, 2024